Neuphoria Therapeutics Inc.
NEUP
$4.66
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -399.14% | 31.04% | 12.50% | 97.61% | 132.19% |
| Total Depreciation and Amortization | 0.00% | -0.09% | 0.02% | -0.03% | -20.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 137.47% | 159.92% | 274.20% | 121.49% | -2,754.58% |
| Change in Net Operating Assets | -3,073.06% | -181.79% | 907.78% | -134.15% | -94.12% |
| Cash from Operations | -2,732.69% | 83.24% | 104.87% | 100.53% | 104.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 668.56% | 445.86% | 24.18% | -84.88% | -72.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | 99.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -103.64% | -93.18% | -97.81% | -100.00% | 1,352.40% |
| Cash from Financing | 134.36% | 131.89% | -64.89% | -89.88% | 0.13% |
| Foreign Exchange rate Adjustments | 4,363.87% | 263.03% | -143.90% | -104.81% | 116.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -73.06% | 406.50% | 11,911.68% | 217.25% | 204.61% |